Gp2 - glycoprotein 2 (zymogen granule membrane) Gene

Also Known as 2310037I18Rik

Species: Mus musculus

Gene Type: protein coding
Gene ID: 67133

Summary

Enables antigen binding activity. Acts upstream of or within antigen transcytosis by M cells in mucosal-associated lymphoid tissue. Located in apical plasma membrane and endosome. Orthologous to human GP2 (glycoprotein 2). [provided by Alliance of Genome Resources, Apr 2022]

Gp2 Products (1)

mRNA Protein Name
NM_025989.4 NP_080265.3 pancreatic secretory granule membrane major glycoprotein GP2 precursor

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence References Source
enables antigen binding IDA
IDA: Inferred from direct assay
19907495 MGI
Biological Process GO Annotation Evidence References Source
acts upstream of or within antigen transcytosis by M cells in mucosal-associated lymphoid tissue IDA
IDA: Inferred from direct assay
19907495 MGI
acts upstream of or within antigen transcytosis by M cells in mucosal-associated lymphoid tissue IMP
IMP: Inferred from mutant phenotype
19907495 MGI
acts upstream of or within establishment of localization in cell IDA
IDA: Inferred from direct assay
19907495 MGI
acts upstream of or within establishment of localization in cell IMP
IMP: Inferred from mutant phenotype
19907495 MGI
Cellular Component GO Annotation Evidence References Source
located in apical plasma membrane IDA
IDA: Inferred from direct assay
19907495 MGI
located in endosome IDA
IDA: Inferred from direct assay
19907495 MGI
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

pancreatic secretory granule membrane major glycoprotein GP2

  • pancreatic zymogen granule membrane protein GP-2

Related Agents

  • Pre-clinical Phase

Pre-clinical Phase

Bioactive Molecules (19)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-173637 AZD0022 Inhibitor 98.36% Unkown
HY-175870 Eras-4001 Inhibitor 98.27% Unkown
HY-159857 Gp(2′-5′)Ap sodium 98.88% Unkown
HY-147089 PRRSV/CD163-IN-1 Inhibitor 98.28% Unkown
HY-173637A (S)-AZD0022 Inhibitor 95.16% Unkown
HY-P1855 HER2/neu (654-662) GP2 98.26% Unkown
HY-107471 CB2 receptor agonist 3 Agonist 99.86% Unkown
HY-RS05609 GP2 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-W1135843 ARN-75039 Inhibitor / Unkown
HY-RS17869 Gp2 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-17367S2 Atazanavir-d9 / Unkown
HY-17367S3 Atazanavir-d5 / Unkown
HY-173329 KRAS-IN-41 Inhibitor / Unkown
HY-17367S4 Atazanavir-d6 99.28% Unkown
HY-179484 KRASG12C IN-19 Inhibitor / Unkown
HY-180885S KRAS G12D-IN-35 Inhibitor / Unkown
HY-P5695 GP-2B Inhibitor / Unkown
HY-RS24338 Gp2 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-U00191 GP2-114 / Unkown
Bioactive MoleculesInhibitory Antibodies (1)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P991450 ADI-15878 Inhibitor 99.80% Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Gp2 NCBI NCBI:2813